What is Orbem?
Orbem AI, a spin-off from the Technical University of Munich, is at the forefront of developing advanced imaging technologies. Their core innovation lies in the fusion of accelerated MRI with sophisticated AI algorithms, enabling detailed, non-invasive analysis of biological and material samples. This technology reveals hidden internal information, making it a powerful tool for applications in sustainable food systems, quality inspection, and early disease detection. By transforming MRI into a fast, accessible, and scalable AI-driven imaging modality, Orbem aims to revolutionize how industries leverage hidden biological data for enhanced efficiency and sustainability. The company is headquartered in Munich and operates with a global team.
How much funding has Orbem raised?
Orbem has raised a total of $96.6M across 2 funding rounds:
Series A
$31.6M
Series B
$65M
Series A (2023): $31.6M with participation from The Venture Collective, Possible Ventures, La Famiglia, and 83North
Series B (2026): $65M led by Supernova Invest, General Catalyst, Possible Ventures, The Venture Collective, 83North, and Innovation Industries
Key Investors in Orbem
Supernova Invest
Supernova Invest is a venture capital firm that supports high-growth deeptech start-ups in sectors like Industrial Technologies, Digital, Healthcare, and Cleantech, providing expertise and patient capital to foster innovation and sustainability.
General Catalyst
General Catalyst is a venture capital firm that invests in transformational business opportunities across multiple sectors and stages, partnering with entrepreneurs to accelerate growth and build enduring enterprises.
Possible Ventures
Possible Ventures is an investment firm focused on backing mission-driven teams leveraging frontier technology to address humanity's most pressing challenges, primarily in pre-seed and seed rounds within climate, energy, health, and society.
What's next for Orbem?
With a significant recent strategic investment and a robust total funding history, Orbem is poised for accelerated scaling and market penetration. The substantial capital infusion, particularly the recent Series B round, indicates strong investor confidence in Orbem's technology and its potential to disrupt multiple industries. This backing will likely fuel further research and development, expansion of their global team, and the scaling of their AI-powered imaging solutions across sectors such as sustainable food systems, industrial quality inspection, and medical diagnostics. The company's focus on deep-tech and AI positions it to capitalize on the growing demand for advanced analytical tools that drive efficiency and sustainability.
See full Orbem company page
